Pellicelli AM, D’Ambrosio C, Dessanti ML, Villani R, Fondacaro L, Miglioresi L, Grillo LR, Andreoli A

Idioma: Ingles.
Referencias bibliográficas: 24
Paginas: 756-761
Archivo PDF: 168.78 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Narang TK, Ahrens W, Russo MW. Post liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl 2010; 16: 1228-35.

2. Taga SA, Washington MK, Terrault N, Wright TL, Somberg KA, Ferrel L. Cholestatic hepatitis C in liver allograft. Liver Transpl Surg 1998; 4: 304-10.

3. Satapathy SK, Sclair S, Fiel MI, Del Rio Martin J, Schiano T. Clinical characterization of patients developing histologically- proven fibrosing cholestatic hepatitis C post-liver transplantation. Hepatol Res 2011; 41: 328-39.

4. Ennishi D, Maeda Y, Niitsu N, Kojima M, Izutsu K, Takizawa J, Kusumoto S, et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large Bcell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 2010; 116: 5119-25.

5. Pellicelli AM, Marignani M, Zoli V, Romano M, Morrone A, Nosotti L, Barbaro G, et al. Hepatitis C virus-related B cell subtypes in non Hodgkin’s lymphoma. World J Hepatol 2011; 3: 278-84.

6. Marignani M, Mangone M, Cox MC, Angeletti S, Veggia B, Ferrari A, di Fonzo M, et al. HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin’s lymphoma treated with rituximab-containing regimens. Dig Liver Dis 2011; 43: 139-42.

7. McCaughan GW, Bowen DG. Pathogenesis of cholestatic hepatitis C. J Hepatol. 2011; 54: 392-94.

8. Torres H A, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 2012; 9: 156-66.

9. de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM, Spinelli JJ, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008; 6: 451-8.

10. Besson C, Canioni D, Lepage E, Pol S, Morel P, Lederlin P, Van Hoof A, et al. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d’Etude des Lymphomes de l’Adulte programs. J Clin Oncol 2006; 24: 953-60.

11. El Saghir NS, Hawkins KA. Hepatotoxicity following vincristine therapy. Cancer 1984; 54: 2006-08.

12. Aubrey DA. Massive hepatic necrosis after cyclophosphamide. Br Med J 1970; 3: 588.

13. Aviles A, Herrera J, Ramos E, Ambriz R, Aguirre J, Pizzuto J, et al. Hepatic injury during doxorubicin therapy. Arch Pathol Lab Med 1984; 108: 912-3.

14. Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P. The late adverse events of rituximab therapy—rare but there! Leuk Lymphoma 2009; 50: 1083-95.

15. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001; 33: 308-10.

16. Takai S, Tsurumi H, Ando K, Kasahara S, Sawada M, Yamada T, Hara T, et al. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy.Eur J Haematol 2005; 74: 158-65

17. Ennishi D, Terui Y, Yokoyama M, Mishima Y, Takahashi S, Takeuchi K, Okamoto H, et al. Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20- positive B-cell lymphoma undergoing rituximab combination chemotherapy. Am J Hematol 2008; 83: 59-62.

18. Arcaini L, Merli M, Passamonti F, Bruno R, Brusamolino E, Sacchi P, Rattotti S, et al. Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin’s lymphomas. Am J Hematol 2010; 85: 46-50.

19. Merli M, Visco C, Spina M, Luminari S, Ferretti VV, Gotti M, Rattotti S, et al. Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica 2014; 99: 489-96.

20. Cunningham-Rundles C,Lieberman P, Hellman G, Chaganti RS. Non Hodgkin lymphoma in common variable immunodeficiency. Am J Hematol 1991; 37: 69-74.

21. Cunningham-Rundles C. Hematologic complications of primary immune deficiencies. Blood Rev 2002; 16: 61-4.

22. Fontana RJ, Hughes EA, Bifano M, Appelman H, Dimitrova D, Hindes R, Symonds WT. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013; 13: 1601-05.

23. Rossotti R, Travi G, Pazzi AM, Baiguera C, Morra E, Puoti M. Rapid clearance of HCV-related splenic marginal zone lymphoma under interferon-free, NS3/NS4A inhibitor-based treatment. A case report. J Hepatol 2015; 62: 234-37.

24. Lyman GH, Dale DC, Friedberg J, Crawford, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol 2004; 22: 4302-11.